Alkermes follows up restructuring with Rodin acqusition

Worth up to $950 million, the deal will give Alkermes access to a preclinical pipeline aimed at diseases rooted in disrupted synapses like Alzheimer's and Parkinson's.

By Jonathan Gardner • Nov. 18, 2019

Dicerna links up with Novo in its 5th, likely final, liver-focused R&D deal

The Danish drugmaker will use the biotech's RNAi platform to develop therapies for diseases like NASH, diabetes and obesity.

By Andrew Dunn • Nov. 18, 2019

Roche wagers $1.4B that Promedior has its next big fibrosis drug

Promedior's main drug targets a lung disease known as idiopathic pulmonary fibrosis and could help Roche once orphan exclusivity runs out on Esbriet.​

By Jacob Bell • Nov. 15, 2019

Sarepta brings in more gene therapies with StrideBio deal

The deal adds four more neuromuscular candidates to the Exondys maker's already-rich pipeline.

By Jonathan Gardner • Nov. 14, 2019

Merck wants to know if taking out cellular trash can treat Alzheimer's

The big pharma is acquiring Calporta Therapeutics to test whether drugs that promote lysosome function can combat neurodegenerative disorders.

By Jacob Bell • Nov. 13, 2019

Amgen's China ambitions become clear with BeiGene deal

Oncology-focused deal will see the biotech take a 21% stake in a Chinese partner and share commercialization of three drugs.

By Jonathan Gardner • Nov. 1, 2019

Roivant, Sumitomo alliance to target cystic fibrosis gene therapy

The companies unveiled the previously unnamed Spirovant as the fifth subsidiary sold to Sumitomo in last month's $3 billion deal.

By Ned Pagliarulo • Oct. 31, 2019

Roche takes aim at hepatitis B, striking R&D deal with Dicerna

The Swiss pharma will pay $200 million while lining up to $1.5 billion in milestones to gain access to a Phase 1 drug and Dicerna's RNAi technology.

By Andrew Dunn • Oct. 31, 2019

What to make of Gilead's latest NASH deal

Gilead and Glympse Bio will test whether synthetic biomarkers can show how badly damaged patients' livers are. It's a partnership that hints at the biotech's commitment to NASH.

By Jacob Bell • Oct. 28, 2019

Pharmacquired: Eylea could be in trouble, but that doesn't make Regeneron a buyer

A rival medicine from Novartis and potential changes to Medicare aren't likely enough for Regeneron to reverse its decades-long aversion to M&A.

By Jacob Bell • Oct. 25, 2019

GSK hands 2 of its less profitable vaccines to Bavarian Nordic

The deal, worth about $335 million upfront, will help GSK simplify its supply chain and allow it to reinvest in higher growth areas, according to the company.

By Jacob Bell • Oct. 21, 2019

Sanofi investing in gene therapy as R&D focus turns toward rare disease

R&D chief John Reed told BioPharma Dive Sanofi is retrofitting a vaccine facility in France to produce the viral vectors needed to deliver gene therapies.

By Andrew Dunn • Oct. 17, 2019

Alexion bids for a smaller version of itself, spurring concerns about the FTC

With the Roche-Spark deal in limbo, analysts are concerned that companies with overlapping pipelines may have trouble completing acquisitions.

By Jacob Bell • Oct. 16, 2019

Reata buys drug rights back from AbbVie for $330M before readout

"It shows our confidence, but we'll have to see how the data plays out," the biotech's CFO told BioPharma Dive.

By Andrew Dunn • Oct. 10, 2019

UCB bets more on rare disease drugs with Ra Pharma acquisition

The $2.5 billion deal hands UCB another late-stage drug for generalized myasthenia gravis, a disease area dominated by Alexion Pharmaceuticals.

By Jacob Bell • Oct. 10, 2019

Feeling pressure in hemophilia, Novo signs gene editing deal with Bluebird

The deal may come too late, though, as the launch of Hemlibra and approach of gene therapies dampens demand for Novo's factor replacement therapies.

By Jonathan Gardner • Oct. 9, 2019

Akcea inks deal with Pfizer, rebounding after leadership shuffle

Two weeks after a mass C-suite departure, a $250 million payment from Pfizer shored up Akcea's finances and enlivened investors in the Ionis affiliate.

By Jonathan Gardner • Oct. 7, 2019

Sobi finds another fit for its dealmaking strategy

The rare disease drugmaker plans to acquire Dova Pharmaceuticals and its blood medicine Doptelet for up to $915 million.

By Jacob Bell • Sept. 30, 2019

Clovis shares plunge after downgrade raises questions on path forward

A Wall Street analyst was skeptical of a preclinical deal that adds R&D costs while the company fights for market share in ovarian cancer.

By Jonathan Gardner • Sept. 24, 2019

Alder's migraine drug attracted plenty of dealmakers. The company, not so much

A new regulatory filing affirms the theory that, in neuroscience, risk-sharing partnerships are more appealing than all-out acquisitions.

By Jacob Bell • Sept. 24, 2019

Lundbeck buys into migraine, acquiring Alder for $2B

The Danish pharma has blockbuster ambitions for Alder's CGRP drug, but the already competitive migraine market is poised to become more so next year.

By Andrew Dunn • Sept. 16, 2019

Vertex makes headway in UK reimbursement

Scotland has agreed to cover two Vertex drugs, Orkambi and Symkevi, which may bode well for resolving a dispute over the company's prices.

By Jacob Bell • Sept. 12, 2019

Reata's new CFO on M&A, weathering a recession and biotech's quirks

Manmeet Soni helped execute multi-billion dollar sales as CFO of Ariad and Pharmacyclics. He's now moving from Alnylam to a small, Texas-based biotech.

By Andrew Dunn • Sept. 12, 2019

Drug companies pay for exclusive access to UK genetic data

Amgen, AstraZeneca, GSK and J&J will get nine months to pour over the first wave of whole genome data coming out of UK Biobank before the global research community gets a chance to look.

By Jacob Bell • Sept. 11, 2019

Sanofi paying Lexicon $260M to exit diabetes alliance

Lexicon had argued Sanofi violated the companies' contract when providing notice in July that it would terminate a research partnership on Zynquista.

By Ned Pagliarulo • Sept. 11, 2019